Trial of Romidepsin and Bortezomib for Multiple Myeloma
Public ClinicalTrials.gov record NCT00765102. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Romidepsin and Bortezomib for Multiple Myeloma Patients With Relapsed or Refractory Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase II, open-label, multicenter, dual-strata study designed to evaluate the efficacy and safety of IV romidepsin given in combination with IV bortezomib for multiple myeloma (MM) patients with refractory or relapsed disease. Patients will be enrolled into one of two strata, bortezomib-resistant or bortezomib non-resistant.
Study identification
- NCT ID
- NCT00765102
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 1, 2008 (Actual)
- Primary completion
- Mar 1, 2010 (Actual)
- Completion
- Mar 1, 2010 (Actual)
- Last update posted
- Nov 25, 2019
2008 – 2010
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Loma Linda University Cancer Center | Loma Linda | California | 92354 | — |
| Desert Cancer Care, Inc | Rancho Mirage | California | 92270 | — |
| Santa Barbara Hematology Oncology Medical Group, Inc. | Santa Barbara | California | 93105 | — |
| James R Berenson, MD, Inc. | West Hollywood | California | 90069 | — |
| Georgia Cancer Specialists I, PC | Atlanta | Georgia | 30341 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Mecklenburg Medical Group | Charlotte | North Carolina | 28204 | — |
| Baylor Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Dallas Oncology Consultants, P.A. | Duncanville | Texas | 75137 | — |
| Oncology Consultants, P.A | Houston | Texas | 77024 | — |
| Central Utah Clinic, PC | Provo | Utah | 84604 | — |
| Virginia Mason Medical Centre | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00765102, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 25, 2019 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00765102 live on ClinicalTrials.gov.